The Administrative and Clinical Core administers the MSA PPG. The Principal investigator (PI) is Dr. Low, who will be assisted by Dr. Sid Gilman (Co-PI), who will have a specific focus on administering the Clinical Core.
The specific aims of Core A are to: 1. Provide supervision and direction for the program project as a whole. 2. Maintain appropriate policies and procedures and manuals as required and ensure that all instruments, such as the Unified Multiple System Atrophy Rating Scale (UMSARS), COMPASS, and COMPASS-change are current. 3. Coordinate the conference calls and meetings of the Steering Committee and the conference calls and meetings of Scientific Advisory Committee (SAC). 4. Provide fiscal control for the operations of the program project, including establishment and maintenance of subcontracts and making payments to projects, cores, and enrolling investigators. 5. Monitor recruitment, the timely transfer of data from sites to the Data Core (Core B), the provision of blood samples to the Genetics Core (Core D), interaction of enrolling sites with Project 1 (Gilman), and the transfer of autopsy samples to the Neuropathology Core (Core C) and Project 2 (Benarroch). 6. Liaison with NINDS and provide performance reports to the Performance and Safety Monitoring Board (PSMB) and liaison with the European MSA study Group. A key function is the integration of activities of the 3 cores and 4 projects by facilitating the flow of information between areas. This function has evolved to a high level over the past 4 years and will be further enhanced. Core A will also facilitate interactions with the Steering Committee and Advisory Board. 7. The Clinical Core houses the double-blind placebo controlled study to evaluate if Rifampicin will halt or reverse progression of neurological and autonomic deficits in eariy cases of MSA. This study is housed in this core to emphasize the important core nature of the study, since it brings together the activities of Projects 1, 3, and 4. 8. Liason with Autonomic Rare Disease Research Consortium (U54 NS065736) in the implementation and supervision of the Rifampicin study.

Public Health Relevance

Multiple system atrophy (MSA) is a progressive and fatal disease. Its cause is unknown and treatment is unsatisfactory. This Program Project is specifically devoted to MSA and focuses on the improved diagnosis, improved understanding of its natural history, and an understanding of what causes the disease. This Core administers the PPG and houses an important treatment trial aimed at halting the progression of the disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS044233-10
Application #
8740562
Study Section
Special Emphasis Panel (ZNS1-SRB-E)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
10
Fiscal Year
2014
Total Cost
$116,968
Indirect Cost
$32,920
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Loavenbruck, Adam J; Singer, Wolfgang; Mauermann, Michelle L et al. (2016) Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? Ann Neurol 80:401-11
Valera, Elvira; Spencer, Brian; Masliah, Eliezer (2016) Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 13:179-89
Labbé, Catherine; Heckman, Michael G; Lorenzo-Betancor, Oswaldo et al. (2016) MAPT haplotype diversity in multiple system atrophy. Parkinsonism Relat Disord 30:40-5
Spencer, Brian; Williams, Stephanie; Rockenstein, Edward et al. (2016) α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. Ann Clin Transl Neurol 3:588-606
Spencer, Brian; Kim, Changyoun; Gonzalez, Tania et al. (2016) α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet 25:1100-15
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Valera, Elvira; Masliah, Eliezer (2016) Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 139 Suppl 1:346-352
Valera, E; Monzio Compagnoni, G; Masliah, E (2016) Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol 42:95-106
Mandler, Markus; Valera, Elvira; Rockenstein, Edward et al. (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 10:10
Low, Phillip A; Reich, Stephen G; Jankovic, Joseph et al. (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14:710-9

Showing the most recent 10 out of 145 publications